All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Researchers at the Barcelona Institute of Science and Technology’s Center for Genomic Regulation (CRG) and Pulmobiotics Ltd. have used one bacterium to fight another. In mouse models, the team used engineered Mycoplasma pneumoniae to treat Pseudomonas aeruginosa, the chief culprit in ventilator-associated pneumonia (VAP).
Chemokine-like receptor 1 (CMKLR1) is a G protein-coupled receptor for chemerin and resolvin E1 that plays a key role in the recruitment and activation of macrophages, natural killer cells and plasmacytoid dendritic cells in inflammatory diseases.
After comparing the response to the two types of vaccines for the respiratory syncytial virus (RSV) based on its fusion protein (F), prefusion (pre-F) versus postfusion (post-F) vaccines, scientists at the National Institutes of Health (NIH) and Astrazeneca plc have demonstrated that targeting the pre-F protein led to better protection. No more bets on RSV immunization based on the post-F protein of the virus. Laboratories can now bet all on red for the pre-F technology.
Genentech Inc. has disclosed 2,8-diazaspiro [4.5] decane compounds acting as serine/threonine-protein kinase LATS1 and/or LATS2 inhibitors reported to be useful for the treatment of acute respiratory distress syndrome (ARDS).
Research at Azcuris Co. Ltd. has led to the development of thymic stromal lymphopoietin (TSLP)/cytokine receptor-like factor 2 (CRLF2; TSLPR) interaction inhibitors, which are reported to be useful for the treatment of autoimmune diseases, chronic obstructive pulmonary disease (COPD), allergy, asthma, allergic rhinitis and chronic rhinosinusitis.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have described NLRP3 inflammasome inhibitors reported to be useful for the treatment of asthma and chronic obstructive pulmonary disease (COPD).
Poolbeg Pharma plc has identified potential new drug candidates from its respiratory syncytial virus (RSV) artificial intelligence (AI) program with Onethree Biotech Inc.
Investigators from Army Medical University reported the discovery and preclinical characterization of a novel cannabinoid receptor 2 (CB2 receptor) agonist, YX-2102, being developed as a potential therapeutic candidate for alleviating lung fibrosis.
Roche has synthesized pyruvate dehydrogenase kinase 1 (PDK1) inhibitors reported to be useful for the treatment of systemic lupus erythematosus, psoriasis, inflammatory bowel diseases, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease and cancer.
Vertex Pharmaceuticals Inc. has received clearance from the FDA for its IND application for VX-522, a messenger ribonucleic acid (mRNA) therapy targeted at treating the underlying cause of cystic fibrosis (CF).
RSS
